VALSTAR PRESERVATIVE FREE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VALSTAR PRESERVATIVE FREE (VALSTAR PRESERVATIVE FREE).
Valrubicin is a semisynthetic anthracycline derivative that intercalates into DNA, inhibiting nucleic acid synthesis and inducing cell death. It is cytotoxic to both dividing and non-dividing cells.
| Metabolism | Valrubicin is primarily metabolized in the liver to its active metabolite, N-trifluoroacetyladriamycin, via enzymatic reduction. Minimal systemic absorption occurs after intravesical administration. |
| Excretion | Renal: approximately 50-70% excreted unchanged in urine within 72 hours; biliary/fecal: minor (<5%). |
| Half-life | Terminal elimination half-life: 3-5 hours; clinical context: supports intravesical instillation with minimal systemic absorption. |
| Protein binding | Approximately 50-60% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | After intravesical administration, systemic absorption limited; apparent Vd is approximately 0.8-1.5 L/kg following IV administration (not clinically used IV); clinical meaning: extensive tissue distribution including bladder mucosa. |
| Bioavailability | Intravesical: negligible systemic bioavailability (<1%) due to limited absorption across bladder epithelium. |
| Onset of Action | Intravesical: clinical effect begins within 24-48 hours; systemic absorption is negligible. |
| Duration of Action | Intravesical: therapeutic effect persists for approximately 30-60 minutes post-instillation; recommended dwell time is 1-2 hours. |
Intravesical instillation of 800 mg (40 mL of 20 mg/mL solution) weekly for 6 weeks, retained in bladder for 2 hours.
| Dosage form | SOLUTION |
| Renal impairment | Valstar is not absorbed systemically after intravesical administration; no dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required based on hepatic function; systemic absorption is negligible. |
| Pediatric use | Safety and efficacy in pediatric patients have not been established; no standard dosing recommendations available. |
| Geriatric use | No specific dose adjustment for elderly patients; intravesical administration results in minimal systemic exposure. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for VALSTAR PRESERVATIVE FREE (VALSTAR PRESERVATIVE FREE).
| Breastfeeding | Unknown whether valrubicin or its metabolites are excreted in human milk. Due to minimal systemic absorption after intravesical administration, risk to nursing infant is low. M/P ratio not available. Use with caution; manufacturer recommends discontinue nursing or drug based on importance to mother. |
| Teratogenic Risk | Valstar (valrubicin) is FDA Pregnancy Category C. Intravesical administration results in negligible systemic absorption, minimizing fetal exposure. No adequate human studies exist. First trimester: potential risk unknown; avoid unless benefit outweighs risk. Second and third trimesters: unlikely to cause fetal harm due to low systemic levels. However, data insufficient to confirm safety. |
■ FDA Black Box Warning
Valstar (valrubicin) should not be used for patients with a known hypersensitivity to valrubicin or any component of the product, or with concurrent urinary tract infection. It should not be used in patients with a perforated bladder, compromised bladder mucosa, or bladder capacity less than 100 mL.
| Serious Effects |
Hypersensitivity to valrubicin or any component; concurrent urinary tract infection; perforated bladder; compromised bladder mucosa; bladder capacity <100 mL.
| Precautions | Contains benzyl alcohol, which has been associated with gasping syndrome in neonates. Not recommended for use in pregnant women. Monitor for bladder irritation, hematuria, and urinary tract infection. Evaluate for bladder contracture. Consider cystectomy if no response. |
Loading safety data…
| Fetal Monitoring | No specific fetal monitoring required due to low systemic absorption. Monitor for local adverse effects (bladder irritation, hematuria). In pregnant patients, standard obstetric monitoring is advised. No need for valrubicin plasma level monitoring. |
| Fertility Effects | Valrubicin is an anthracycline derivative with potential gonadotoxicity; however, intravesical administration limits systemic exposure. No specific human data on fertility. Animal studies have not been conducted with intravesical route. Consider risk of reduced fertility with systemic anthracyclines, but unlikely with local therapy. |